<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02189967</url>
  </required_header>
  <id_info>
    <org_study_id>STR-PORTAF-2014</org_study_id>
    <nct_id>NCT02189967</nct_id>
  </id_info>
  <brief_title>Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation</brief_title>
  <official_title>Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Consortium for Translational Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Radiation Research in Oncology Dresden/Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Oncology Working Group of the German Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized multicentric phase II study it will be investigated whether an accelerated
      postoperative radiotherapy with photons or protons (7 fractions per week, 2 Gy single dose)
      may improve locoregional tumour control in non-small cell lung cancer (NSCLC) in comparison
      to conventional fractionation (5 fractions per week, 2 Gy single dose).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized multicentric trial. Within this study an accelerated irradiation
      schedule (7 fractions per week, 2 Gy single dose) will be compared with the currently used
      conventional fractionation schedule (5 fractions per week, 2 Gy single dose) for
      postoperative radiotherapy with photons or protons in patients with NSCLC. The primary
      endpoint is locoregional tumour control after 36 months. Secondary endpoints are overall
      survival of patients, local recurrence-free and distant metastases-free survival after 36
      months, acute and late toxicity as well as quality of life for both treatment methods.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of local tumor control</measure>
    <time_frame>36 months after therapy</time_frame>
    <description>Local tumor control will be assessed by appropriate non-invasive (CT or PET-CT) and if necessary invasive examination methods (bronchoscopy with biopsy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>36 months after therapy</time_frame>
    <description>Follow-up visits should be continued in all patients until death. Otherwise patients will be censored with date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence-free survival</measure>
    <time_frame>36 months after therapy</time_frame>
    <description>Local-recurrences will be assessed by appropriate non-invasive (CT or PET-CT) and if necessary invasive examination methods (bronchoscopy with biopsy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>Comparison after 20, 50, 100 and 200 patients have been treated. This number of patients is expected to be included after 6, 12, 18 and 40 months.</time_frame>
    <description>The occurrence of acute side effects (up to 90 days after start of treatment) will be recorded and documented based on CTCAE 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>36 months after therapy</time_frame>
    <description>The assessment of quality of life is carried out using the established EORTC QLQ-C30 questionnaire and the additional lung module QLQ-LC13. Quality of life will be documented immediately before the start of therapy, after completion of postoperative radiotherapy and at every follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant metastases-free survival</measure>
    <time_frame>36 months after therapy</time_frame>
    <description>Distant metastases will be assessed by PET-CT or abdominal sonography and chest x-ray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late toxicity</measure>
    <time_frame>Comparison after 20, 50, 100 and 200 patients have been treated. This number of patients is expected to be included after 6, 12, 18 and 40 months.</time_frame>
    <description>The occurrence of late side effects will be recorded and documented based on CTCAE 4.0 after every follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">308</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>conventional fractionation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radiotherapy with conventional fractionation (5 x 2Gy per week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>accelerated fraction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radiotherapy with accelerated fraction (7 x 2 Gy per week)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>conventional fractionation</intervention_name>
    <description>In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.</description>
    <arm_group_label>conventional fractionation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>accelerated fraction</intervention_name>
    <description>In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.</description>
    <arm_group_label>accelerated fraction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed non-small cell lung cancer

          -  previous tumor resection with curative intention

          -  postoperative indication for irradiation (&gt; pN1 and/ or R1)

          -  R2-resection or recurrence postoperative/after adjuvant chemotherapy diagnosed by the
             restaging-imaging

          -  exclusion of distant metastases (M0)

          -  age &gt; 18 years

          -  good general condition (ECOG performance status 0 or 1)

          -  written informed consent

          -  appropriate compliance to ensure close follow-up

          -  women of childbearing age: adequate contraception

        Exclusion Criteria:

          -  histologically confirmed small cell lung cancer

          -  distant metastases

          -  no written informed consent or lack of cooperation relating to therapy or follow-up

          -  previous (&lt; 5 years) or concomitant other malignant disease (exception: malignant
             disease, which is very likely healed and not influenced therapy or follow up of the
             non-small cell lung cancer, e.g. carcinoma in-situ, basaliomas, very early skin
             cancers)

          -  for proton therapy: heart pacemaker

          -  previous radiotherapy of the thorax or lower neck region

          -  pregnancy or lactation

          -  participation in another intervention study or not completed follow-up of a
             intervention study. Exceptions are psychological studies, supportive or observation
             studies, the previous therapy of non-small cell lung cancer is in accordance with the
             guideline and the participation in radiotherapy studies is not excluded in the trial
             protocol of the previous study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Bütof, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dresden University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Therapy and Radiation Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Bütof, Dr.</last_name>
    <phone>+49 351 458 2238</phone>
    <email>str.studien@uniklinikum-dresden.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Baumann, Prof.</last_name>
      <phone>+49 351 458 2238</phone>
      <email>str.studien@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Michael Baumann, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rainer Fietkau, Prof.</last_name>
      <phone>+49 9131 85 33405</phone>
    </contact>
    <investigator>
      <last_name>Rainer Fietkau, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anca Grosu, Prof.</last_name>
      <phone>+49 761 270 94610</phone>
    </contact>
    <investigator>
      <last_name>Anca Grosu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale), Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>Halle</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Vordermark, Prof.</last_name>
      <phone>+49 345 557 4310</phone>
    </contact>
    <investigator>
      <last_name>Dirk Vordermark, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis für Strahlentherapie Hamburg-Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Heide, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Jürgen Heide, Dr.</last_name>
      <phone>040 / 866 910-80</phone>
      <email>info@strahlentherapie-harburg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jürgen Debus, Prof.</last_name>
      <phone>+49 6221 / 56 82 01</phone>
    </contact>
    <investigator>
      <last_name>Jürgen Debus, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes, Department of Radiotherapy and Radiation Oncology</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Rübe, Prof.</last_name>
      <email>radioonkologie@uks.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heinz Schmidberger, Prof.</last_name>
      <phone>+49 6131 17-3851</phone>
    </contact>
    <investigator>
      <last_name>Heinz Schmidberger, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München,Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Belka, Prof.</last_name>
      <phone>+49 89 7095 4520</phone>
    </contact>
    <investigator>
      <last_name>Claus Belka, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technische Universität München, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>Rostock</city>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Hildebrandt, Prof.</last_name>
      <phone>+49 0381 - 494 9000</phone>
    </contact>
    <investigator>
      <last_name>Guido Hildebrandt, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marienhospital Stuttgart, Department of Radiotherapy and Palliative Medicine</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Hehr, Prof.</last_name>
      <email>strahlentherapie@vinzenz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>Tübingen</city>
        <zip>72016</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Zips, Prof.</last_name>
      <phone>+49 7071/29-8 21 65</phone>
    </contact>
    <investigator>
      <last_name>Daniel Zips, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne, Department of Radiation Therapy and Radiation Oncology</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rafał Dziadziuszko, Prof.</last_name>
      <phone>+48 58 349 2271</phone>
    </contact>
    <investigator>
      <last_name>Rafał Dziadziuszko, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SPZOZ MSW; Warmia &amp; Mazury Oncology Center; Warmia &amp; Mazury Medical University</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-228</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucyna Kępka, Dr.</last_name>
      <email>lucynak@coi.waw.pl</email>
    </contact>
    <investigator>
      <last_name>Lucyna Kępka, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Poland Cancer Center, Department of Radiotherapy</name>
      <address>
        <city>Poznań</city>
        <zip>61-866</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Piotr Milecki, Prof.</last_name>
      <email>piotr.milecki@wco.pl</email>
    </contact>
    <investigator>
      <last_name>Piotr Milecki, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>July 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2014</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität Dresden</investigator_affiliation>
    <investigator_full_name>Dr. Rebecca Bütof</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>accelerated fractionation</keyword>
  <keyword>conventional fractionation</keyword>
  <keyword>postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

